Corix Bioscience (Corix Bioscience) EV-to-EBIT : 0.00 (As of Jun. 18, 2024)

Corix Bioscience EV-to-EBIT Chart

Corix Bioscience Quarterly Data
	Oct12	Jan13	Apr13	Jul13	Oct13	Jan14	Apr14	Jul14	Oct14	Jan15	Apr15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17
EV-to-EBIT	Get a 7-Day Free Trial															-10.11	-3.45	-3.03	-3.82	-4.43

Competitive Comparison of Corix Bioscience's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Corix Bioscience's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Corix Bioscience's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Corix Bioscience's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Corix Bioscience's EV-to-EBIT falls into.

Corix Bioscience EV-to-EBIT Calculation

Corix Bioscience's EV-to-EBIT for today is calculated as:

Corix Bioscience's current Enterprise Value is $0.00 Mil.
Corix Bioscience's EBIT for the trailing twelve months (TTM) ended in Sep. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.94 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Corix Bioscience  (GREY:CXBS) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Corix Bioscience's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2017 is calculated as:

Corix Bioscience's Enterprise Value for the quarter that ended in Sep. 2017 was $23.03 Mil.
Corix Bioscience's EBIT for the trailing twelve months (TTM) ended in Sep. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.94 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Corix Bioscience EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Corix Bioscience's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Corix Bioscience (Corix Bioscience) Business Description